UPLOAD Filing
CITIUS ONCOLOGY, INC.
Date: Aug. 22, 2025 · CIK: 0001851484 · Accession: 0000000000-25-009017
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Citius Oncology, Inc. Draft Registration Statement on Form S-3 Submitted August 20, 2025 CIK No. 377-08347 Dear Leonard Mazur:
August 22, 2025
Leonard Mazur Chief Executive Officer Citius Oncology, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Alexander M. Donaldson, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 22, 2025 Leonard Mazur Chief Executive Officer Citius Oncology, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 Re: Citius Oncology, Inc. Draft Registration Statement on Form S-3 Submitted August 20, 2025 CIK No. 377-08347 Dear Leonard Mazur: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexander M. Donaldson, Esq. </TEXT> </DOCUMENT>